Spero Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
SPRO$1.07+3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber | Exhibit Description | Filed withthis Report | Incorporated byReference herein fromForm or Schedule | Filing Date | SEC File /RegistrationNumber |
|---|---|---|---|---|---|
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | Form 8-K (Exhibit 3.1) | 11/6/2017 | 001-38266 | |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant | Form 8-K (Exhibit 3.1) | 8/18/2021 | 001-38266 | |
| 3.3 | Amended and Restated Bylaws of the Registrant | Form 10-Q(Exhibit 3.1) | 11/13/2023 | 001-38266 | |
| 10.1# | 2017 Stock Incentive Plan, as Amended | Form 8-K (Exhibit 10.1) | 6/3/2024 | 001-38266 | |
| 10.2# | Amended and Restated Employment Agreement, dated June 13, 2023, by and between the Registrant and Satyavrat Shukla | Form 10-Q(Exhibit 10.3) | 8/10/2023 | 001-38266 | |
| 10.3# | Interim Period Agreement, dated January 10, 2025, by and between the Registrant and Satyavrat Shukla | Form 8-K(Exhibit 10.1) | 1/10/2025 | 001-38266 | |
| 10.4# | Retention Letter Agreement, dated November 13, 2024, by and between the Registrant and Satyavrat Shukla | Form 10-K(Exhibit 10.12) | 3/27/2025 | 001-38266 | |
| 10.5# | Separation Agreement, dated April 28, 2025, by and between the Registrant and Satyavrat Shukla | X | |||
| 10.6# | Separation Agreement, dated July 30, 2024 by and between the Registrant and Kamal Hamed, M.D. | Form 10-Q(Exhibit 10.2) | 11/14/2024 | 001-38266 | |
| 10.7# | Employment Agreement, dated January 1, 2020, by and between the Registrant and Timothy Keutzer | Form 10-K(Exhibit 10.12) | 3/16/2020 | 001-38266 | |
| 10.8# | Retention Letter Agreement, dated November 13, 2024, by and between the Registrant and Timothy Keutzer | Form 10-K(Exhibit 10.19) | 3/27/2025 | 001-38266 | |
| 10.9# | Employment Agreement, dated October 31, 2023 by and between the Registrant and Esther Rajavelu | Form 10-Q(Exhibit 10.1) | 5/15/2024 | 001-38266 | |
| 10.10# | Amended and Restated Employment Agreement, dated April 28, 2025, by and between the Registrant and Esther Rajavelu | X | |||
| 10.11# | Interim Period Agreement, dated January 10, 2025, by and between the Registrant and Esther Rajavelu | Form 8-K(Exhibit 10.2) | 1/10/2025 | 001-38266 | |
| 10.12# | Retention Letter Agreement, dated November 13, 2024, by and between the Registrant and Esther Rajavelu | Form 10-K(Exhibit 10.22) | 3/27/2025 | 001-38266 | |
| 10.13# | Consulting Agreement, effective as of August 5, 2024, by and between the Registrant and John C. Pottage, Jr., M.D. | Form 10-Q(Exhibit 10.3) | 11/14/2024 | 001-38266 | |
| 10.14# | Amended and Restated Consulting Agreement, effective as of January 29, 2025, by and between the Registrant and John C. Pottage, Jr., M.D. | Form 10-K(Exhibit 10.28) | 3/27/2025 | 001-38266 | |
| 10.15† | Amendment 3 to Exclusive License Agreement, dated March 4, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited | Form 10-Q(Exhibit 10.4) | 5/15/2024 | 001-38266 | |
| 10.16† | Amendment 4 to Exclusive License Agreement, dated October 28, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited | Form 10-Q(Exhibit 10.4) | 11/14/2024 | 001-38266 | |
| 19.1 | Spero Therapeutics, Inc. Insider Trading Policy, effective as of June 5, 2023 | Form 10-K(Exhibit 19.1) | 3/27/2025 | 001-38266 | |
| 31.1 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32* | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Principal Executive Officer and Principal Financial Officer | X | |||
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.